Further evidence of fetuin-B’s participation in MASLD etiopathogenesis is provided by the discovery that dietary therapeutic interventions lowering fetuin-B levels by about 9.5% have been observed to increase insulin sensitivity, therefore underscoring its possible use as a therapy target [84]. Here, FETUB is linked to metabolic dysfunction-associated steatotic liver disease.